Devices, digital health, and the technology changing how care is delivered.
Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week.
Eli Lilly’s up-to-$2.3 billion acquisition of Ajax Therapeutics is facing its first major public test, and the initial clinical data show why the pharma giant made the bet.
Neoantigen-based therapies are considered one of the most promising approaches in modern immuno-oncology. One challenge continues to limit the field: accurately identifying which neoantigens will generate meaningful anti-tumor immunity.
Neumora's navacaprant has completed a clean sweep of trial misses in major depressive disorder.
A federal jury in Delaware has found that Amgen and its acquired Teneobio willfully infringed on an antibody patent held by Harbour Antibodies, a Dutch subsidiary of China’s Harbour BioMed.
With Johnson & Johnson gradually fleshing out its $55 billion U.S. investment scheme in recent months, the New Jersey-headquartered drug and medical device giant on Monday revealed just how the plan will benefit its medtech operations, specifically in the field of vision care.
Nature Index’s latest research rankings show that China continues to be the clear leader in contributions to scientific journals, with a 22% increase between 2024 and 2025. While China remains well ahead of the rest of the top 10, nearly 10% growth in journal contributions from Japan and South Korea outpaced higher-ranked Western countries such as the U.S., Germany and the U.K.
The company's SPY002 prompted a 10.7-point reduction from baseline levels in patients’ Robart’s Histopathology Index (RHI) scores by week 12.
Executives told Fierce how the company is in the middle of a transition to “the new Biogen”—embracing partnerships, investment and entrepreneurship to replenish its pipeline.
Adaptive Biotechnologies is planning to separate its drug discovery and diagnostics businesses, outlining its intent to evaluate “strategic and structural alternatives” for the medicine wing of the company
AI drug design specialist Protillion has inked a $510 million biobucks collaboration and license agreement with Merck & Co. that brings together Protillion’s platform and Merck’s drug discovery expertise.
Medical device maker iRhythm has been hit by a cyberattack, but the company said the incident has not affected its core products, operations or ability to meet patient needs.
As biopharma companies of all stripes devote more time and attention to AI-based drug discovery and development, healthcare PE firm Altaris is bolstering its presence in the field through M&A.
The FDA gave the green light to Dexcom’s over-the-counter glucose monitor Stelo for children 2 years or older who don’t use insulin.
Eli Lilly is taking another shot at the pain market, continuing a recent M&A binge that shows no signs of slowing down.
With a panel of outside experts set to weigh in Thursday—and with a refusal-to-file fiasco with the FDA just barely in the rearview—Moderna and its contender for the United States’ first mRNA-based influenza vaccine are heading into a critical test this week.
Jazz Pharmaceuticals is looking to bolster its oncology research bona fides via a partnership with AbCellera to discover and develop T-cell-engaging (TCE) antibodies that could result in up to $820 million in biobucks for each program that Jazz options.
With pharma and life sciences deal values surpassing $65 billion in the first quarter, marking the strongest quarter in the industry since 2020, analysts from PwC have declared that the “biopharma ecosystem is back to full health.”
The FDA has pulled a U-turn on uniQure’s Huntington’s disease gene therapy, giving the biotech the OK to file for accelerated approval after previously demanding data from another trial.
Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company’s subcutaneously delivered antibodies for migraine prevention.
John Tsai, M.D., is rounding out his global drug development resume. Immediately after landing at Daiichi Sankyo, the pharma veteran finds himself leading the R&D portion of the antibody-drug conjugate specialist’s new five-year plan, which aims to lay the groundwork for Daiichi to become a global top 5 oncology company by 2035.
Biogen has struck a backloaded, $1 billion deal to buy RayThera, snagging a pipeline of anti-inflammatory drug candidates led by a prospect on the cusp of clinical development.
Innoviva has revealed the next steps for Langer Lab assets it rescued from Lyndra Therapeutics’ collapse, launching Nortiva Bio to develop long-acting oral medicines and pursue drug development alliances.
In another biotech born out of China’s “NewCo” model, cAMPfield Therapeutics has launched with a $180 million series A and a focus on oral medicines for inflammatory diseases.